Not Yet RecruitingEarly Phase 1

Aspirin Dosing in Pregnancy

United States30 participantsStarted 2026-04-15

Plain-language summary

The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.

Who can participate

Age range18 Years – 50 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pregnant people prior to 17 weeks * Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates * Age 18-50 years * Singleton viable gestation * Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors. Exclusion Criteria: * Undergoing glucose challenge test (GCT) at time of blood draw * Allergy or intolerance to aspirin * Antithrombotic or antiplatelet therapy * Anemia (hemoglobin \<10 g/dl) or thrombocytopenia (platelet count \<100,000), or thrombocytosis (platelet count \>600,000) * Known hemorrhagic diathesis * Planned delivery outside of NYU

What they're measuring

Measures of platelet aggregation assessed by Light Transmission Aggregometry (LTA)

Timeframe: Baseline, 4 weeks after initiation of aspirin

Trial details

NCT IDNCT07525635

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-01

Contact for this trial

Christina A. Penfield, MD, MPH

646-754-2700 Christina.Penfield@nyulangone.org

View on ClinicalTrials.gov More Preeclampsia Possible trials